Betsy Sleath1, Robyn Sayner2, Michelle Vitko3, Delesha M Carpenter4, Susan J Blalock5, Kelly W Muir6, Annette L Giangiacomo7, Mary Elizabeth Hartnett8, Alan L Robin9. 1. Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB# 7573, Chapel Hill, NC 27599-7573, USA; Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, CB # 7590, Chapel Hill, NC 27599-7590, USA. Electronic address: betsy_sleath@unc.edu. 2. Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB# 7573, Chapel Hill, NC 27599-7573, USA. Electronic address: sayner@unc.edu. 3. Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB# 7573, Chapel Hill, NC 27599-7573, USA. Electronic address: mlvitko@email.unc.edu. 4. Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB# 7573, Chapel Hill, NC 27599-7573, USA. Electronic address: dmcarpenter@unc.edu. 5. Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, CB# 7573, Chapel Hill, NC 27599-7573, USA. Electronic address: s_blalock@unc.edu. 6. Department of Ophthalmology, School of Medicine, Duke University and Durham VA Medical Center, Health Services Research and Development, 2351 Erwin Rd #3802, Durham, NC 27705, USA. Electronic address: muir0009@mc.duke.edu. 7. Ophthalmology, Emory University School of Medicine, 1365B Clifton Rd, Atlanta, GA 30322, USA. Electronic address: agianci@emory.edu. 8. Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center University of Utah, 65 N Mario Capecchi, Salt Lake City, UT 84132, USA. Electronic address: ME.Hartnett@hsc.utah.edu. 9. Ophthalmology and International Health, Johns Hopkins School of Medicine, 600 N Wolfe St, Baltimore, MD 21287, USA; Department of Ophthalmology, University of Maryland, 419 West Redwood St., Suite 420, Baltimore, MD 21201, USA; Department of Ophthalmology, University of Michigan, 1000 Wall St., Ann Arbor, MI 48105, USA. Electronic address: arobin@glaucomaexpert.com.
Abstract
OBJECTIVE: The purpose of this study was to: (a) describe the extent to which ophthalmologists and glaucoma patients discuss vision quality-of-life during office visits, and (b) examine the association between patient and ophthalmologist characteristics and provider-patient communication about vision quality-of-life. METHODS: Patients with glaucoma who were newly prescribed or on glaucoma medications were recruited at six ophthalmology clinics. Patients' visits were video-tape recorded and quality-of-life communication variables were coded. Generalized estimating equations were used to analyze the data. RESULTS: Two hundred and seventy-nine patients participated. Specific glaucoma quality-of-life domains were discussed during only 13% of visits. Older patients were significantly more likely to discuss one or more vision quality-of-life domains than younger patients. African American patients were significantly less likely to make statements about their vision quality-of-life and providers were less likely to ask them one or more vision quality-of-life questions than non-African American patients. CONCLUSION: Eye care providers and patients infrequently discussed the patient's vision quality-of-life during glaucoma visits. African American patients were less likely to communicate about vision quality-of-life than non-African American patients. PRACTICE IMPLICATIONS: Eye care providers should make sure to discuss vision quality-of-life with glaucoma patients.
OBJECTIVE: The purpose of this study was to: (a) describe the extent to which ophthalmologists and glaucomapatients discuss vision quality-of-life during office visits, and (b) examine the association between patient and ophthalmologist characteristics and provider-patient communication about vision quality-of-life. METHODS:Patients with glaucoma who were newly prescribed or on glaucoma medications were recruited at six ophthalmology clinics. Patients' visits were video-tape recorded and quality-of-life communication variables were coded. Generalized estimating equations were used to analyze the data. RESULTS: Two hundred and seventy-nine patients participated. Specific glaucoma quality-of-life domains were discussed during only 13% of visits. Older patients were significantly more likely to discuss one or more vision quality-of-life domains than younger patients. African American patients were significantly less likely to make statements about their vision quality-of-life and providers were less likely to ask them one or more vision quality-of-life questions than non-African American patients. CONCLUSION: Eye care providers and patients infrequently discussed the patient's vision quality-of-life during glaucoma visits. African American patients were less likely to communicate about vision quality-of-life than non-African American patients. PRACTICE IMPLICATIONS: Eye care providers should make sure to discuss vision quality-of-life with glaucomapatients.
Authors: Betsy Sleath; Susan J Blalock; Delesha M Carpenter; Robyn Sayner; Kelly W Muir; Catherine Slota; Scott D Lawrence; Annette L Giangiacomo; Mary Elizabeth Hartnett; Gail Tudor; Jason A Goldsmith; Alan L Robin Journal: Ophthalmology Date: 2014-12-24 Impact factor: 12.079
Authors: B Sleath; D M Carpenter; S J Blalock; R Sayner; K W Muir; C Slota; A L Giangiacomo; M E Hartnett; G Tudor; A L Robin Journal: Health Educ Res Date: 2015-09-02
Authors: Simon Smith; Muhammad Arsyad Bin Nordin; Tom Hinchy; Patrick Henn; Colm M P O'Tuathaigh Journal: Eur Geriatr Med Date: 2020-07-26 Impact factor: 1.710
Authors: Cecilia N Hollenhorst; Vanessa Elliott; Michele Heisler; Kevin Schneider; Ken Resnicow; Paula Anne Newman-Casey Journal: Ophthalmol Glaucoma Date: 2020-05-07